SCHEMBL6069148

SCHEMBL6069148

Cc1onc(-c2ccncc2)c1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.62
MAPK1 P28482 2/20 0.62
KMT2A Q03164 4/20 0.58
GAA P10253 2/20 0.58
MEN1 O00255 2/20 0.58
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 3/20 0.55
HPGD P15428 1/20 0.55
HSD17B10 Q99714 1/20 0.55
HTT P42858 3/20 0.53
POLB P06746 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TSHR P16473 4/20 0.49
USP2 O75604 1/20 0.48
ALOX15 P16050 1/20 0.47
LMNA P02545 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316093 0.86 KMT2A (0.76) SMN1; SMN2MAPK1KMT2AGAAMEN1
Hydrochloric Acid SCHEMBL4846563 0.85 KMT2A (0.73) SMN1; SMN2MAPK1KMT2AGAAMEN1
SCHEMBL3862966 0.85 KMT2A (0.59) SMN1; SMN2MAPK1KMT2AGAAMEN1
SCHEMBL12310938 0.83 KMT2A (0.58) SMN1; SMN2MAPK1KMT2AGAAMEN1
SCHEMBL7769050 0.83 KMT2A (0.58) SMN1; SMN2MAPK1KMT2AGAAMEN1
SCHEMBL457706 0.82 GPBAR1 (0.59) SMN1; SMN2KMT2AGAAMEN1ALDH1A1
SCHEMBL7771555 0.82 KMT2A (0.60) SMN1; SMN2MAPK1KMT2AGAAMEN1
SCHEMBL1246411 0.82 KMT2A (0.56) SMN1; SMN2MAPK1KMT2AGAAMEN1
SCHEMBL3548012 0.82 GPBAR1 (0.66) KMT2AGAAMEN1ALDH1A1KDM4E
SCHEMBL16333641 0.81 ALDH1A1 (0.63) SMN1; SMN2MAPK1KMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227467-B1 ISOXAZOLO-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-12-31 EP disclosed
US-7060710-B2 Isoxazole pyrazoloindane derivatives as cognition enhancing GABAA α5 subtype ligands MERCK SHARP & DOHME LTD. (GB) 2006-06-13 US disclosed
US-7053219-B2 Isoxazolopyridone derivatives and their use BANYU PHARMACEUTICAL CO. LTD. (JP) 2006-05-30 US disclosed
US-20040176407-A1 Novel isoxazolopyridone derivatives and their use BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-09-09 US disclosed
EP-1408042-A1 NOVEL ISOXAZOLOPYRIDONE DERIVATIVES AND USE THEREOF BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-14 EP disclosed
US-20040006226-A1 Isoxazole pyrazoloindane derivatives as cognition enhancing GABA-A alpha 5 subtype ligands MERCK SHARP & DOHME LTD. (GB) 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006226-A1 Isoxazole pyrazoloindane derivatives as cognition enhancing GABA-A alpha 5 subtype ligands GABRA5, GABRB1, GABRA4 SMN1; SMN2 2855/4885MAPK1 4083/4885KMT2A 3319/4885
US-20040176407-A1 Novel isoxazolopyridone derivatives and their use GRIN2A, GRM2, GRM1 SMN1; SMN2 1300/4885MAPK1 1978/4885KMT2A 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.